Clinical Factors Affecting the Response to Osimertinib in Non-Small Cell Lung Cancer Patients with An Acquired Epidermal Growth Factor Receptor T790M Mutation: A Long-Term Survival Analysis

被引：0
|
作者：
Ya Chen
Shuyuan Wang
Bo Zhang
Yiming Zhao
Lele Zhang
Minjuan Hu
Wei Zhang
Baohui Han
机构：
[1] Shanghai Jiao Tong University,Department of Pulmonary, Shanghai Chest Hospital
来源：
Targeted Oncology | 2020年 / 15卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：337 / 345
页数：8
相关论文
共 50 条
  • [21] Real-world osimertinib pretreatment experience in patients with epidermal growth factor receptor T790M mutation-positive locally advanced or metastatic non-small cell lung cancer
    Chang, Gee-Chen
    Shih, Jin-Yuan
    Yu, Chong-Jen
    Chao, Heng-Sheng
    Yang, Cheng-Ta
    Lin, Chien-Chung
    Hung, Jen-Yu
    Hsiao, Sheng-Yen
    Wang, Chin-Chou
    Chian, Chih-Feng
    Hsia, Te-Chun
    Chen, Yuh-Min
    PLOS ONE, 2024, 19 (05):
  • [22] Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non-small cell lung cancer cell line
    Ogino, Atsuko
    Kitao, Hiroyuki
    Hirano, Seiki
    Uchida, Akiko
    Ishiai, Masamichi
    Kozuki, Toshiyuki
    Takigawa, Nagio
    Takata, Minoru
    Kiura, Katsuyuki
    Tanimoto, Mitsune
    CANCER RESEARCH, 2007, 67 (16) : 7807 - 7814
  • [23] Epidermal growth factor receptor T790M mutation as a prognostic factor in EGFR-mutant non-small cell lung cancer patients that acquired resistance to EGFR tyrosine kinase inhibitors
    Ma, Guangzhi
    Zhang, Jing
    Jiang, Hai
    Zhang, Nannan
    Yin, Liyuan
    Li, Wen
    Zhou, Qinghua
    ONCOTARGET, 2017, 8 (59) : 99429 - 99437
  • [24] Resistant Patterns to Osimertinib in Non-Small Cell Lung Cancer Patients with Both T790M and Sensitizing EGFR Mutation
    Lee, J. C.
    Yang, S.
    Oh, D. K.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S806 - S807
  • [25] The impact of T790M mutation status for later-line osimertinib in non-small cell lung cancer patients with progression on frontline epidermal growth factor receptor tyrosine kinase inhibitor
    Jei, T. Y.
    Wu, C-E.
    Yang, C. T.
    ANNALS OF ONCOLOGY, 2022, 33 : S1588 - S1588
  • [26] Predictors of osimertinib response at second-line treatment in EGFR mutant non-small cell lung cancer patients with acquired T790M resistance mutation
    Dogan, I.
    Gurbuz, M.
    Paksoy, N.
    Khanmamadov, N.
    Vatansever, S.
    Saip, P.
    Demirkazik, A.
    Aydiner, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S1351 - S1351
  • [27] Epidermal Growth Factor Receptor T790M Mutation Testing in Non-Small Cell Lung Cancer: An International Collaborative Study to Assess Molecular EGFR T790M Testing in Liquid Biopsy
    Filipits, Martin
    Kainz, Verena
    Sebek, Viktor
    Zach, Herwig
    Liquid Biopsy Collaborative Study Grp
    CANCERS, 2023, 15 (13)
  • [28] Epidermal growth factor receptor T790M mutations in non-small cell lung cancer (NSCLC) of Yunnan in southwestern China
    Zhou, Yongchun
    Ma, Yuhui
    Shi, Hutao
    Du, Yaxi
    Huang, Yunchao
    SCIENTIFIC REPORTS, 2018, 8
  • [29] Epidermal growth factor receptor T790M mutations in non-small cell lung cancer (NSCLC) of Yunnan in southwestern China
    Yongchun Zhou
    Yuhui Ma
    Hutao Shi
    Yaxi Du
    Yunchao Huang
    Scientific Reports, 8
  • [30] Epidermal growth factor receptor T790M mutation-positive metastatic non-small-cell lung cancer: focus on osimertinib (AZD9291)
    Saad, Nibal
    Poudel, Aarati
    Basnet, Alina
    Gajra, Ajeet
    ONCOTARGETS AND THERAPY, 2017, 10 : 1757 - 1765
12345